Abstracts tagged "Citrulline and osteoclastogenesis"

Abstract Number: 1188 • 2012 ACR/ARHP Annual Meeting
Fibrinogen Induced Inhibition of Osteoclastogenesis Is Reversed by Citrullination of Fibrinogen by Peptidylarginine Deiminase
Eun Young Lee¹, Ji Soo Kim², Hye Won Kim³, Sung Hae Chang⁴, Jin-Su Song⁵, Hie-Joon Kim⁵, Kyung-Hyun Park-Min⁶, Lionel B. Ivashkiv⁷, Eun Bong Lee⁸ and Yeong Wook Song⁹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Seoul National University College of Medicine, Seoul, South Korea, ³Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, ⁴Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁵Department of Chemistry, Seoul National University, Seoul, South Korea, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁸Seoul National University, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine,, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: There are increasing evidences that autoantibodies and immune complexes (ICs) containing citrullinated fibrinogen are present in rheumatoid arthritis (RA) patients' sera and contribute to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].